Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS +0.32%12 Price-to-Tangible-Book is 5.99 as of Aug. 27, 2026. GuruFocus rates KMTS with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 701 Medical Devices & Instruments companies, Kestra Medical Technologies ranks worse than 76.18% on this metric.
The historical rank and industry rank for Kestra Medical Technologies's Price-to-Tangible-Book or its related term are showing as below:
KMTS'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.66 Med: 5.34 Max: 6.12
Current: 5.99
During the past 6 years, Kestra Medical Technologies's highest Price to Tangible Book Ratio was 6.12. The lowest was 4.66. And the median was 5.34.
KMTS's Price-to-Tangible-Book is ranked worse than 76.18% of 701
companies
in the Medical Devices & Instruments industry
Industry Median: 2.65
vs KMTS: 5.99
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Kestra Medical Technologies Price-to-Tangible-Book Related Terms
Kestra Medical Technologies Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies Price-to-Tangible-Book Chart
KMTS vs AZTA, STAA, BLFS: Price-to-Tangible-Book Comparison
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Kestra Medical Technologies (KMTS) has a Price-to-Tangible-Book of 5.99 as of Aug. 27, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Kestra Medical Technologies and its competitors. According to the industry distribution chart, Kestra Medical Technologies ranks #534 out of 701 companies in the Medical Devices & Instruments industry, placing it in the top 76.2%.
Is Kestra Medical Technologies' Price-to-Tangible-Book too high?
Kestra Medical Technologies' current Price-to-Tangible-Book is 5.99. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.65. Kestra Medical Technologies' value of 5.99 is 126% above this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #534 out of 701 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Price-to-Tangible-Book compare to AZTA and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #534 out of 701 companies for Price-to-Tangible-Book. This places Kestra Medical Technologies in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.65. Kestra Medical Technologies' value of 5.99 is 126% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.65, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current Price-to-Tangible-Book of 5.99 is 126% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current Price-to-Tangible-Book is 5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Price-to-Tangible-Book of 5.99. The current Price-to-Tangible-Book is 5.99 and 126% above the Medical Devices & Instruments industry median of 2.65. Kestra Medical Technologies' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Price-to-Tangible-Book is 5.99 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score
Get the complete analysis for KMTS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
